# Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

> **NCT01162122** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 7109 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
- **BIOLOGICAL:** Non-adjuvanted trivalent subunit influenza vaccine (TIV)

## Key facts

- **NCT ID:** NCT01162122
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-11
- **Target enrollment:** 7109 (ACTUAL)
- **Last updated:** 2014-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162122, "Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01162122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*